Cancer drug Alecensa gets breakthrough therapy designation
Alecensa received its first FDA BTD in June 2013
PHOTO: Reuters
Roche said on Tuesday its lung cancer drug Alecensa (alectinib), developed by its Genentech unit, received a second breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for its anaplastic lymphoma kinase (ALK) inhibitor.
Promising drugs stoke talk of eventual cancer "cure"
The latest breakthrough therapy designation was granted for the treatment of adult patients with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received prior treatment with an ALK inhibitor, the Swiss drugmaker said in a statement.
12 ways to staying cancer-free
Alecensa received its first FDA BTD in June 2013 for people with ALK-positive NSCLC whose disease progressed on treatment with crizotinib, Basel-based Roche said.
Promising drugs stoke talk of eventual cancer "cure"
The latest breakthrough therapy designation was granted for the treatment of adult patients with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received prior treatment with an ALK inhibitor, the Swiss drugmaker said in a statement.
12 ways to staying cancer-free
Alecensa received its first FDA BTD in June 2013 for people with ALK-positive NSCLC whose disease progressed on treatment with crizotinib, Basel-based Roche said.